Plasma bilirubin and late graft failure in renal transplant recipients

Transplant International

Volumn 25, Issue 8, 2012, Pages 876-881

  Deetman, Petronella E ^a   Zelle, Dorien M ^a   Homan Van Der Heide, Jaap J ^a   Navis, Gerjan J ^a   Gans, Reinold O B ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

bilirubin; chronic allograft dysfunction; graft failure; oxidative stress

Indexed keywords

BILIRUBIN; CALCINEURIN INHIBITOR; LIVER ENZYME;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

BILIRUBIN; FEMALE; GRAFT REJECTION; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84863720643     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01515.x     Document Type: Article

References (27)

1. Merville P,. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 2005; 65: 615.
2. Meier-Kriesche HU, Schold JD, Kaplan B,. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
3. Paul LC,. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
5. Sayegh MH, Carpenter CB,. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004; 351: 2761.
6. Kim J, Seok YM, Jung KJ, Park KM,. Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol 2009; 297: F461.
7. Djamali A, Sadowski EA, Muehrer RJ, et al. BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. Am J Physiol Renal Physiol 2007; 292: F513.
8. Raj DS, Lim G, Levi M, Qualls C, Jain SK,. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am J Kidney Dis 2004; 43: 154.
9. Albrecht EW, Stegeman CA, Tiebosch AT, Tegzess AM, van Goor H,. Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant 2002; 2: 448.
10. Abraham NG, Asija A, Drummond G, Peterson S,. Heme oxygenase-1 gene therapy: recent advances and therapeutic applications. Curr Gene Ther 2007; 7: 89.
11. Duann P, Lianos EA,. GEC-targeted HO-1 expression reduces proteinuria in glomerular immune injury. Am J Physiol Renal Physiol 2009; 297: F629.
12. Baranano DE, Rao M, Ferris CD, Snyder SH,. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002; 99: 16093.
13. Adin CA, Croker BP, Agarwal A,. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288: F778.
14. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
15. van Ree RM, de Vries AP, Oterdoom LH, et al. Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation. Transplantation 2009; 88: 279.
16. van Ree RM, Oterdoom LH, de Vries AP, et al. Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant 2007; 22: 246.
17. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL,. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
18. Giral P, Ratziu V, Couvert P, et al. Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis 2010; 210: 607.
19. Fujii M, Inoguchi T, Sasaki S, et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78: 905.
20. Schwertner HA, Jackson WG, Tolan G,. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18.
21. Temme EH, Zhang J, Schouten EG, Kesteloot H,. Serum bilirubin and 10-year mortality risk in a belgian population. Cancer Causes Control 2001; 12: 887.
22. Zucker SD, Horn PS, Sherman KE,. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40: 827.
23. Ollinger R, Wang H, Yamashita K, et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007; 9: 2175.
24. Ryter SW, Tyrrell RM,. The heme synthesis and degradation pathways: role in oxidant sensitivity. heme oxygenase has both pro- and antioxidant properties. Free Radic Biol Med 2000; 28: 289.
25. Yamashita K, McDaid J, Ollinger R, et al. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J 2004; 18: 765.
26. Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, Pepys MB,. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 2003; 158: 357.
27. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387.